Creatinine Test Market
Creatinine Test Market - Global Industry Assessment & Forecast
- By Test Type Blood Test, Urine Test, Others
- By Product Consumables, Instruments
- By Application Urinary Tract Obstruction, Renal Failure, Kidney Cancer, Glomerulonephritis, Others
- By End Use Hospital and Clinics, Diagnostic Centre, Research Institutes
- By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
|Forecast Years:||2022 - 2028|
|Historical Years:||2016 - 2021|
|Revenue 2021:||USD 995.1 Million|
|Revenue 2028:||USD 2,356.7 Million|
|Revenue CAGR (2022 - 2028):||16.1%|
|Fastest Growing Region (2022 - 2028)||Asia Pacific|
|Largest Region (2021):||North America|
- Cross-segment Market Size and Analysis for Mentioned Segments
- Additional Company Profiles (Upto 5 With No Cost)
- Additional Countries (Apart From Mentioned Countries)
- Country/Region-specific Report
- Go To Market Strategy
- Region Specific Market Dynamics
- Region Level Market Share
- Import Export Analysis
- Production Analysis
- Others Request Customization Speak To Analyst
Global Creatinine Test market is valued at USD 995.1 Million in 2021 and is projected to attain a value of USD 2,356.7 Million by 2028 at a CAGR of 16.1% during the forecast period, 2022–2028. Over the forecast period, the global Creatinine Test market is expected to increase significantly. Muscle metabolism produces creatinine as an endogenous by-product. This waste product is measured in the clinical laboratory to determine the glomerular filtration rate (GFR), which further describes the renal function of patients. Jaffe's kinetic methods and enzymatic methods are used in the majority of modern creatinine assays.
Increased creatinine levels in the urine, together with an abrupt decline in urine output, are usually indicators of AKI or ARF. As a result, the rise in and high rate of hypoalbuminemia caused by COVID-19 (coupled with the growing elderly population and other variables) is predicted to increase the number of instances of AKI/ARF, thereby supporting market growth in the first half of the forecasted period.
Rising Prevalence of Kidney Disorders
Creatinine Test Market Size, 2021 To 2028 (USD Million)
Kidney disease is a leading cause of death all over the world. Multiple renal therapies necessitate constant monitoring of components like creatinine and albumin, as well as their ratios, which necessitates the use of multiple urine analysis products and procedures. Urine analysis is commonly used in the diagnosis and treatment of renal disorders. Clinicians can use biochemical urine analysis to determine the levels of chemical substances in the urine (such as creatinine, urobilinogen, bilirubin, ketones, and glucose). Chronic kidney illness, acute kidney injury, and acute renal failure are all indicated by abnormal levels of these chemicals in the urine. As a result, the rising prevalence of renal illnesses will be the primary growth driver for this market, ensuring that demand for albumin and creatinine tests remains stable.
High Cost of Automated Analyzers
Most small hospitals and clinics still favour semi-automated technology or manual analysis due to smaller workloads. Large hospitals with heavy workloads are more likely to adopt automated instruments, therefore the revenue generated can justify the expenditures of implementing automated analyzers. This makes it difficult for automated analyzers to break into the market, particularly in emerging economies, posing a significant barrier to industry expansion.
The Creatinine Test market scope can be tabulated as below:
The Global Creatinine Test Market can be segmented by Test Type into Blood Test, Urine Test and Others. By Product into Consumables and Instruments. By Application into Urinary Tract Obstruction, Renal Failure, Kidney Cancer, Glomerulonephritis and Others. By End-Use into Hospital and Clinics, Diagnostic Centre and Research Institutes. Based on Region, the Creatinine Test Market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Below tree is interactive. You can click the nodes to get more information.
North America to Continue Dominating the Creatinine Test Market
Owing to the high prevalence of the condition and the rise in government programmes to aid early diagnosis, North America held the biggest market share in 2019.The increased prevalence of various kidney illnesses, well-developed technology, high healthcare expenditures, and the existence of prominent players are all factors contributing to this. The European market for creatinine is the second-largest. Increasing government backing, rising healthcare expenditures, and well-developed technology are the market's key driving forces.
Key participants operating in the Creatinine Test market are: BioAssay Systems, Abcam plc, Arbor Assays, Thermo Fisher Scientific, Randox Laboratories Ltd., Sentinel CH. SpA, DiaSys Diagnostic Systems GmbH, MedTest Holdings, Inc. (Pointe Scientific, Inc.), Abbexa Ltd., and General Atomics, Inc. (Diazyme Laboratories, Inc.).
The Creatinine Test market is segmented as follows:
|Regions & Countries Covered||
|Report Coverage||Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, technology landscape, patent analysis, market attractiveness analysis by segments and North America, company market share analysis, and COVID-19 impact analysis|
Frequently Asked Question
The global Creatinine Test valued at USD 995.1 Million in 2020 and is expected to reach USD 2,356.7 Million in 2028 growing at a CAGR of 16.1%.
The prominent players in the market are BioAssay Systems, Abcam plc, Arbor Assays, Thermo Fisher Scientific, Randox Laboratories Ltd., Sentinel CH. SpA, DiaSys Diagnostic Systems GmbH, MedTest Holdings, Inc. (Pointe Scientific, Inc.), Abbexa Ltd., and General Atomics, Inc. (Diazyme Laboratories, Inc.)..
The market is project to grow at a CAGR of 16.1% between 2021 and 2028.
The driving factors of the Creatinine Test include
- Rising Prevalence of Kidney Disorders
North America was the leading regional segment of the Creatinine Test in 2020.